Investor Relations

Investor Relations Home

Stock Information
Corporate Profile

Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to addressing unmet needs of patients by bringing innovative solutions to the field of dermatology. The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo. Having completed Phase II clinical trials of these product candidates, the company expects ... More >>

Recent NewsMore >>
DateTitle 
02/23/17Foamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation ForumPrinter Friendly Version
02/22/17Foamix Reports Year End 2016 Financial Results and Provides Business UpdatePrinter Friendly Version
02/07/17Foamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22Printer Friendly Version
02/06/17Foamix Pharmaceuticals to Present at the 2017 BIO CEO & Investor ConferencePrinter Friendly Version
Upcoming EventsMore >>
DateTitle
03/02/17 10:50 a.m. ET
Foamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation Forum
R Room, Hyatt Regency, Orlando
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Foamix Pharmaceuticals Ltd posts new information to the site. Just enter your e-mail address and click Submit.